TXNIP and prostate cancer: As shown above for the BCa cell line MCF7, DASA-58 treatment also strongly reduced TXNIP levels in the prostate cancer cell line LnCap, an effect that was also independent of TXNIP proteasomal degradation (supplementary figure S3).